EUVIMEDEUVIMED entdecken
Open Access

Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production

Ella N Perrault iD, Jack M Shireman iD, Eunus S Ali iD, Peiyu Lin, Isabelle Preddy, Cheol Park iD, Shreya Budhiraja, Shivani Baisiwala, Karan Dixit iD, C David James iD, Dieter H Heiland, Issam Ben-Sahra iD und 4 weitere

Science Advances · 19.05.2023 · 9 (20)

DOI: 10.1126/sciadv.ade7236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 19.05.2023. Verfasst von Ella N Perrault und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Ribonucleotide Reductases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During therapy, adaptations driven by cellular plasticity are partly responsible for driving the inevitable recurrence of glioblastoma (GBM). To investigate plasticity-induced adaptation during standard-of-care chemotherapy temozolomide (TMZ), we performed in vivo single-cell RNA sequencing in patient-derived xenograft (PDX) tumors of GBM before, during, and after therapy. Comparing single-cell transcriptomic patterns identified distinct cellular populations present during TMZ therapy. Of interest was the increased expression of ribonucleotide reductase regulatory subunit M2 ( RRM2 ), which we found to regulate dGTP and dCTP production vital for DNA damage response during TMZ therapy. Furthermore, multidimensional modeling of spatially resolved transcriptomic and metabolomic analysis in patients’ tissues revealed strong correlations between RRM2 and dGTP. This supports our data that RRM2 regulates the demand for specific dNTPs during therapy. In addition, treatment with the RRM2 inhibitor 3-AP (Triapine) enhances the efficacy of TMZ therapy in PDX models. We present a previously unidentified understanding of chemoresistance through critical RRM2-mediated nucleotide production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaRibonucleotide ReductasesDrug Resistance, NeoplasmHumansCell Line, TumorTemozolomide

Substanzen

Ribonucleotide ReductasesTemozolomide

Autor:innen und Institutionen

  • Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Microenvironment and Immunology Research Laboratory, Medical-Center, University of Freiburg, Freiburg, Germany.
  • Department of Neurosurgery, Medical-Center, University of Freiburg, Freiburg, Germany.

ORCID-Profile: Ella N Perrault, Jack M Shireman, Eunus S Ali, Cheol Park, Karan Dixit, C David James, Issam Ben-Sahra, Sebastian Pott, Anindita Basu, Jason Miska, Atique U Ahmed

Förderung

  • NINDS NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Perrault, E. N., Shireman, J. M., Ali, E. S., Lin, P., Preddy, I., Park, C., Budhiraja, S., Baisiwala, S., Dixit, K., James, C. D., Heiland, D. H., Ben-Sahra, I., Pott, S., Basu, A., Miska, J., & Ahmed, A. U. (2023). Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Science Advances, 9(20). https://doi.org/10.1126/sciadv.ade7236

Vancouver

Perrault EN, Shireman JM, Ali ES, Lin P, Preddy I, Park C, et al. Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Science Advances. 2023;9(20). doi:10.1126/sciadv.ade7236

BibTeX
@article{Perrault2023,
  author = {Perrault, Ella N and Shireman, Jack M and Ali, Eunus S and Lin, Peiyu and Preddy, Isabelle and Park, Cheol and Budhiraja, Shreya and Baisiwala, Shivani and Dixit, Karan and James, C David and Heiland, Dieter H and Ben-Sahra, Issam and Pott, Sebastian and Basu, Anindita and Miska, Jason and Ahmed, Atique U},
  title = {Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {20},
  doi = {10.1126/sciadv.ade7236}
}
Kostenlos starten →